New Two-Year Deucravacitinib Data Reinforce Durable Efficacy and Consistent Safety Profile in Treatment of Moderate to Severe Plaque Psoriasis Pharmaceutical Investing
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Volta Inc. of Class Action Lawsuit and Upcoming Deadline - VLTA; VLTA WS Pharmaceutical Investing
BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights Pharmaceutical Investing
Potent Ventures Receives Conditional Approval from the Canadian Securities Exchange for the Change of Business to the Gummy Project Biotech Investing
ABBV Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of June 6, 2022 Deadline in Securities Fraud Class Action Lawsuit Against AbbVie, Inc. Pharmaceutical Investing
CLASS ACTION UPDATE for ABBV, BKKT and MULN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders Pharmaceutical Investing
CLASS ACTION UPDATE for IBM, SDIG and AUPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders Pharmaceutical Investing
Upadacitinib Achieved Clinical Remission and Endoscopic Response at One Year in Phase 3 Maintenance Study in Patients with Crohn's Disease Pharmaceutical Investing
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPH Pharmaceutical Investing
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against AbbVie, Inc. Pharmaceutical Investing
